Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;21(8):541-547.
doi: 10.2217/pgs-2019-0195. Epub 2020 May 6.

HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium

Affiliations

HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium

Vincent Gagné et al. Pharmacogenomics. 2020 Jun.

Abstract

Aim: To evaluate the association between human leukocyte antigen (HLA) alleles and native Escherichia coli asparaginase hypersensitivity (AH) in children with acute lymphoblastic leukemia (ALL) who received Dana-Farber Cancer Institute treatment protocols. Patients & methods:HLA-DQA1, HLA-DRB1 and HLA-DQB1 alleles were retrieved from available whole exome sequencing data of a subset of childhood ALL patients from Quebec ALL cohort and analyzed for an association with AH. PCR assay was developed to analyze associated alleles in the entire discovery and replication cohorts. Results: Two alleles in linkage disequilibrium (HLA-DRB1*07:01 and DQA1*02:01) were associated with AH. Additional analyses, performed to distinguish between HLA-DRB1*07:01 haplotypes with and without DQB1*02:02 allele, showed that the association was dependent on the presence of DQB1*02:02. Conclusion: This study confirms the implication of HLA-DRB1*07:01, DQA1*02:01 and DQB1*02:02 alleles in developing AH in childhood ALL.

Keywords: SNP; acute lymphoblastic leukemia; asparaginase; asparaginase hypersensitivity; human leukocyte antigen; pharmacogenetics.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This study was supported by the Canadian Institute for Cancer Research, Leukemia Lymphoma Society of Canada, Cancer Research Society and Charles Bruneau Foundation. Dana-Farber Cancer Institute ALL treatment protocols are supported by the National Cancer Institute/NIH grant 5 P01CA06848. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Similar articles

Cited by

References

    1. Abaji R, Krajinovic M. Current perspective on pediatric pharmacogenomics. Expert Opin. Drug Metab. Toxicol. 12(4), 363–365 (2016). - PubMed
    1. Egler RA, Ahuja SP, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J. Pharmacol. Pharmacother. 7(2), 62–71 (2016). - PMC - PubMed
    1. Silverman LB, Stevenson KE, O'Brien JE. et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000). Leukemia 24(2), 320–334 (2010). - PMC - PubMed
    1. Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk. Lymphoma 56(8), 2273–2280 (2015). - PMC - PubMed
    1. van der Sluis IM, Vrooman LM, Pieters R. et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica 101(3), 279–285 (2016). - PMC - PubMed

Publication types

MeSH terms